Jiangsu Lianhuan Pharmaceutical Co Ltd Market Cap ($537.18 Million)
Market Cap & Net Worth: Jiangsu Lianhuan Pharmaceutical Co Ltd (600513)
Jiangsu Lianhuan Pharmaceutical Co Ltd market cap. Jiangsu Lianhuan Pharmaceutical Co Ltd (SHG:600513) has a market capitalization of $537.18 Million (CN¥3.67 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #11511 globally and #3243 in its home market, demonstrating a 0.55% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Lianhuan Pharmaceutical Co Ltd's stock price CN¥12.86 by its total outstanding shares 285456270 (285.46 Million). Also see Jiangsu Lianhuan Pharmaceutical Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Jiangsu Lianhuan Pharmaceutical Co Ltd Market Cap History (2015–2026)
Jiangsu Lianhuan Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $595.19 Million to $537.18 Million (2.21% CAGR). Check today's stock price for Jiangsu Lianhuan Pharmaceutical Co Ltd for real-time trading data and today's change.
Jiangsu Lianhuan Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Lianhuan Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Jiangsu Lianhuan Pharmaceutical Co Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.19x
Jiangsu Lianhuan Pharmaceutical Co Ltd's market cap is 0.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.92x
Jiangsu Lianhuan Pharmaceutical Co Ltd's market cap is 4.92 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $595.19 Million | $642.43 Million | $50.11 Million | 0.93x | 11.88x |
| 2016 | $520.47 Million | $604.86 Million | $62.69 Million | 0.86x | 8.30x |
| 2017 | $339.19 Million | $689.10 Million | $70.55 Million | 0.49x | 4.81x |
| 2018 | $234.60 Million | $1.02 Billion | $73.56 Million | 0.23x | 3.19x |
| 2019 | $310.46 Million | $1.29 Billion | $79.73 Million | 0.24x | 3.89x |
| 2020 | $413.88 Million | $1.39 Billion | $103.00 Million | 0.30x | 4.02x |
| 2021 | $392.50 Million | $1.65 Billion | $118.84 Million | 0.24x | 3.30x |
| 2022 | $386.45 Million | $1.96 Billion | $141.37 Million | 0.20x | 2.73x |
| 2023 | $465.33 Million | $2.17 Billion | $135.01 Million | 0.21x | 3.45x |
| 2024 | $413.95 Million | $2.16 Billion | $84.16 Million | 0.19x | 4.92x |
Competitor Companies of 600513 by Market Capitalization
Companies near Jiangsu Lianhuan Pharmaceutical Co Ltd in the global market cap rankings as of November 8, 2026. Also see Jiangsu Lianhuan Pharmaceutical Co Ltd balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Jiangsu Lianhuan Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Jiangsu Lianhuan Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Jiangsu Lianhuan Pharmaceutical Co Ltd's market cap moved from $595.19 Million to $ 537.18 Million, with a yearly change of 2.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥537.18 Million | -29.77% |
| 2025 | CN¥764.83 Million | +84.76% |
| 2024 | CN¥413.95 Million | -11.04% |
| 2023 | CN¥465.33 Million | +20.41% |
| 2022 | CN¥386.45 Million | -1.54% |
| 2021 | CN¥392.50 Million | -5.17% |
| 2020 | CN¥413.88 Million | +33.31% |
| 2019 | CN¥310.46 Million | +32.34% |
| 2018 | CN¥234.60 Million | -30.84% |
| 2017 | CN¥339.19 Million | -34.83% |
| 2016 | CN¥520.47 Million | -12.56% |
| 2015 | CN¥595.19 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Jiangsu Lianhuan Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $537.18 Million USD |
| MoneyControl | $537.18 Million USD |
| MarketWatch | $537.18 Million USD |
| marketcap.company | $537.18 Million USD |
| Reuters | $537.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jiangsu Lianhuan Pharmaceutical Co Ltd
Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprili… Read more